Skip to main content
. 2021 Jul-Dec;11(2):59–70. doi: 10.5005/jp-journals-10018-1344

Fig. 3.

Fig. 3

Increase in HLA-DR expression in lymphocytes and monocytes of patients treated with HeberNasvac or in the control group between (day 0 vs 4 and day 0 vs 8). In both cases, the HLA-DR antigen presentation marker increased their frequency and intensity